<DOC>
	<DOCNO>NCT02397473</DOCNO>
	<brief_summary>The main purpose study evaluate efficacy safety study drug know LY2951742 participant episodic cluster headache .</brief_summary>
	<brief_title>A Study LY2951742 Participants With Episodic Cluster Headache</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Cluster Headache</mesh_term>
	<criteria>Participants history episodic cluster headache least two cluster period last 7 day 1 year ( untreated ) separate painfree remission period â‰¥1 month . Participants able distinguish cluster headache attack headache . Current enrollment discontinuation within last 30 day , clinical trial involve investigational drug device . Current use prior exposure calcitoningenerelated peptide ( CGRP ) antibody , antibody CGRP receptor , antibody nerve growth factor ( NGF ) . Are take indomethacin and/or suspect another distinct trigeminal autonomic cephalalgia . A history migraine variant could implicate could confuse ischemia . Known hypersensitivity multiple drug , monoclonal antibody therapeutic protein . A history presence medical illness indicate medical problem would preclude study participation . Evidence significant active unstable psychiatric disease , opinion investigator . Women pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>